



CERTIFICATE of ATTENDANCE

This certifies that

Richard Burt

attended the following event:

Cellular therapies and transplantation for autoimmunity and cancer

on

Monday, March 4, 2019

at

The Royal Society of Medicine

Bridget Gildea

Director of Learning

Education Department

This event has been accredited with 5 CPD Points **RCP Code: 124264**

Important Cookie Information - this message will appear only once.

To give you the best possible experience, this site uses cookies and by continuing to use the site you agree that we can save them on your device.

Cookies are small text files which are placed on your computer and which remember your preferences/some details of your visit. Our cookies don't collect personal information. For more information, please read our [privacy policy](#) or visit the [cookies page](#), which also explains how to disable cookies if you wish to.



The ROYAL
SOCIETY of
MEDICINE

[login](#)
[search RSM](#)



[Location ▶](#)

[Call us ▶](#)

[Email ▶](#)

ptm03 - cellular therapies an...


cellular therapies and
transplantation for autoimmunity and
cancer

Date **Monday 4 March 2019**
Day

Venue **Royal Society of Medicine
1 Wimpole Street
LONDON
W1G 0AE ▶**

Organised by [Pathology Section](#)

Accreditation **CPD - Applied for**



about this event

This meeting covers several main areas of emerging clinical and scientific progress in the area of stem cell transplantation.

Diseases areas that will be covered include: multiple sclerosis, scleroderma, and haematological malignancies. Presentations on major recent clinical and scientific breakthroughs from clinicians, experts, scientific researchers and world leaders in the field. As well as perspectives from patients and regulatory bodies. Talks from patients, NHS England, and NICE will provide insight into the experience of living with the disease, public health perspectives on cost and treatment access.

topics include:

- Clinical perspectives on new developments in stem cell transplantation therapies and how it impacts patient management
- A biomedical research perspective on emerging topics in cellular transplant therapies and remaining challenges
- Patient perspectives on living with MS, scleroderma, haematological malignancies
- Regulatory/government body perspectives (NHS/NICE/MP) on how emerging cellular transplantation therapies may be regulated and accessed by patients

keynote speaker

Dr Richard Burt, Chief of Immunotherapy and Autoimmune Diseases in the Department of Medicine at Northwestern Feinberg School of Medicine in Chicago, Illinois, USA.

Dr Burt's Department, the Division of Immunotherapy and Autoimmune Diseases (DIAD) is the **only centre in the world** devoted to a unique area of treatment and research utilizing stem cell transplantation in clinical trials for autoimmune diseases and vascular diseases. DIAD pioneered and performed America's first hematopoietic stem cell transplants to treat: Multiple Sclerosis (MS), Diabetes, Lupus, Crohn's, Rheumatoid Arthritis, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Phephigus, Dermatomyositis, Devic's, Myasthenia Gravis, Polymyositis and Scleroderma.

His lecture titled "An update on the MIST (Multiple sclerosis International Stem cell Transplantation) trial" will provide information on the aims and the outcomes of the **first and only trial of its kind testing haematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis**. As an investigator involved in the trial, Dr Burt can provide unique insights into what this trial means for the future of MS treatment. While the first part of the study demonstrated that this type of stem cell transplantation can be delivered with acceptable safety, the longer-term evaluation is still underway until 2021 and thus an update on the MIST trial will be of great interest to an international audience. Dr Burt will also participate in the panel discussion titled "Should stem cell transplantation be the first-line treatment for multiple sclerosis."

other key speakers include:

- **Professor Paolo Muraro**, Senior Academic in the Division of Brain Sciences, Department of Medicine. Professor Muraro serves as Deputy Head of Division (Education and Training) and directs the Clinical Neuroimmunology Group within the Centre for Neuroinflammation and Neurodegeneration.
- **Professor John Snowden**, Consultant Haematologist, Director of Blood and Marrow Transplantation and Honorary Professor of Haemato-oncology & Stem Cell Transplantation Department of Haematology Sheffield Teaching Hospitals NHS Foundation Trust. He is also a member of Leukaemia UK's Medical Panel.
- **Dr. Martin Pule**, Clinical Senior Lecturer Honorary Consultant in Haematology, Research Department of Haematology, Cancer Institute, Faculty of Medical Sciences, University College London.

rates

RSM member: £39 - £96

Non member: £65 - £160

* Following registration you will be contacted by email with; your booking confirmation, feedback survey and attendance certificate. For full details of the RSM privacy policy, [click here](#).

agenda

9.00 am Registration, tea and coffee

Welcome and introduction

9.30 am Dr Amit Patel, President, Pathology
Section, Royal Society of Medicine

9.40 am All-Party Parliamentary Group on stem cell
transplantation

SESSION ONE: MULTIPLE SCLEROSIS (MS)

10.00 am What is MS?

10.10 am Living with MS
Patient, MS Society

10.20 am Keynote lecture: An update on the MIST
trial

10.40 am Haematopoietic stem cell transplantation
for MS

11.00 am Tea and coffee break

SESSION TWO: HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR AUTOIMMUNE DISEASES

11.40 am NHS Transplant Clinical Reference Group
- MS

11.50 am Panel debate: Should stem cell
transplantation be first line treatment for
MS?

All speakers

12.30 pm Lunch

SESSION THREE: SCLERODERMA

2.40 pm Overview of haematological malignancies for CAR T therapy including: Leukemia, lymphoma, myeloma

2.50 pm Living with a haematological malignancy
Patient, Bloodwise Charity

3.00 pm Keynote lecture: CAR T cell therapy

3.20 pm Managing the complications of CAR T cell therapy

3.30 pm NHS Transplant Clinical Reference Group - haematological malignancy

3.40 pm New developments in CAR T cell therapy

Closing remarks

3.50 pm Dr Amit Patel, President, Pathology Section, Royal Society of Medicine

Close of meeting

4.00 pm Evaluation surveys and certificates will be sent by email

4.05 pm Student and trainee question and answers session

[register now for this event](#)

[register for this event](#)